Proactive therapy of atopic dermatitis – an emerging concept
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a chronic and highly pruritic skin disease with a broad spectrum of clinical manifestations. Atopic dermatitis has clearly increased by two- to threefold (prevalence of 15–30% in children and 2–10% in adults) during the past three decades in industrialized countries. As it is one of the most common of the skin diseases in developed countries, it has an increasing socio-economical impact. The direct cost is estimated almost 1 billion dollar in the United States alone (1). Pruritus, sleep loss, dietary restrictions and psychosocial affectations significantly lower the quality of life of AD patients (2). The common long-term treatment concept for AD is based on daily application of emollients with or without antibacterial ingredients accompanied with symptomatic anti-inflammatory therapy consisting of topical glucocorticosteroids (TCS) or topical calcineurin inhibitors (TCI) on an 'as needed' basis (3, 4). This 'reactive' treatment approach is well established, widely accepted and the legal basis for all licensed TCS and TCI. Experienced physicians tailor this approach to every patient by choosing the optimal emollient and anti-inflammatory compounds eventually combined with UV-light, antihistamines and other treatment options. Recently, an alternative treatment approach has been evaluated in clinical trials. This 'proactive' approach starts with an intensive topical anti-inflammatory therapy until all lesions have mostly cleared, followed by long-term, low-dose intermittent application of anti-inflammatory therapy to the previously affected skin together with daily application of emollients to unaffected areas. On the one hand, identification of the most suitable treatment approach for AD as such calls for general evidence from basic science and immunobiology. On the other hand, clinical efficacy and safety studies, quality of life assessments and pharmaco-economic data can only be produced by comparing specific, well-defined treatment strategies in clinical trials. As a long-term clinical trial comparing the proactive and reactive approach has been published in a recent issue of Allergy (5), this editorial covers general evidence from basic science and immunobiology as well as recent trial data supporting long-term proactive treatment strategies. Defects of epidermal barrier function in AD lesions are mirrored by less pronounced, but clearly detectable similar defects in nonlesional AD skin, as recently reviewed by Proksch et al. (6). This barrier dysfunction results in an increased outside-in permeability of the stratum corneum for allergens in AD skin (7), corresponding to an increased inside-out permeability that may be assessed by measuring the transepidermal water loss in both lesional and nonlesional AD skin (8). The barrier dysfunction of nonlesional skin in close proximity to AD lesions is more pronounced than in regions distant from the florid lesions (9). The increased permeability of nonlesional AD skin for large protein allergens is an important factor for the atopy patch test (10). Thus, protein allergens dissolved in petrolatum penetrate the epidermal barrier and elicit an eczematous skin reaction to the respective proteins (11). Atopic dermatitis skin has been investigated by profilometric examination, showing intermediate smoothness levels for nonlesional AD skin, which are below normal skin but better than lesional AD (12). An analysis of the epidermal lipids essential for skin barrier function showed lower results for extractable long-chain fatty acids not just in lesional AD skin (75%) but also in nonlesional AD skin (60%) (13). Finally, several loss of function mutations of the Filaggrin gene have recently been detected in high association with AD (14, 15), leading to a barrier defect and reflecting the clinical association of ichthyosis vulgaris to AD well known to clinicians for many years (16). This constitutive component of the barrier defect adds to the recently described, inflammation-induced component of the barrier defect (17) and will not go away even if the eczema is adequately treated. The histopathology of nonlesional AD skin revealed features of mild disease with a low-grade inflammatory infiltrate, swelling of the endothelial cells, and thickening of the basement membrane zone (18). Immunohistology showed that epidermal Langerhans cells are carrying IgE via the high-affinity IgE-receptor in lesional as well as in nonlesional skin of AD, but not in normal skin from nonatopic individuals (19–22). Quantitative flow cytometry demonstrated that Langerhans cells expresses significantly more high-affinity IgE-receptors on the cell surface in nonlesional AD skin than in normal human skin (23). In conclusion, there is overwhelming evidence that normal-looking, nonlesional AD skin is not 'normal' at all, but is characterized by a clinically meaningful barrier function defect and a sub-clinical eczematous skin reaction. The key parameters of clinical efficacy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978 · cited 1×
“Finally, several loss of function mutations of the Filaggrin gene have recently been detected in high association with AD (14, 15), leading to a barrier A.”
BackgroundBieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Self-citationBieber, T., de la Salle, H., Wollenberg, A., Hakimi, J., Chizzonite, R., Ring, J., Hanau, D., & de la Salle, C. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1285 · Cited by 481
Self-citation
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationGuidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citationBieber, T. (2010) · Annals of Dermatology · doi:10.5021/ad.2010.22.2.125 · Cited by 557
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationWollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13599 · Cited by 395
Self-citation
Metadata
- Authors
- Wollenberg, A., & Bieber, T.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 64
- Issue
- 2
- Pages
- 276-278
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2003946862
- Cited by
- 143
- References
- 3
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proactive therapy of atopic dermatitis – an emerging concept. https://app.cochat.ai/papers/10.1111/j.1398-9995.2008.01803.x
- The paper
- Wollenberg, A., & Bieber, T. (2009). Proactive therapy of atopic dermatitis – an emerging concept. Allergy. https://doi.org/10.1111/j.1398-9995.2008.01803.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.